US-based Azurity Pharmaceuticals Inc announced on Tuesday that the US Food and Drug Administration (FDA) has approved XIFYRM (meloxicam injection), an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.
XIFYRM is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. XIFYRM provides a non-opioid analgesic in a 30mg/mL vial for IV bolus injection over 15 seconds. Because of delayed onset of analgesia, XIFYRM alone is not recommended for use when rapid onset of analgesia is required.
"XIFYRM demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," commented Ron Scarboro, Azurity Pharmaceuticals CEO. "XIFYRM addresses an important clinical need, especially for patients requiring a non-opioid component to multimodal analgesia strategies."
Azurity Pharmaceuticals expects XIFYRM to be available in the coming weeks.
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Rakuten Medical signs manufacturing agreement with LOTTE Biologics
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
Curasight reports preliminary data from Phase 1 trial in patients with high-grade gliomas
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations